Annals of Oncology Advance Access originally published online on June 9, 2006
Annals of Oncology 2006 17(7):1035-1036; doi:10.1093/annonc/mdl115
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
editorial |
Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
Toronto Sunnybrook Regional Cancer Center, Toronto, Canada
(E-mail: kathy.pritchard@sunnybrook.ca)
| The first 10% of the full text of this article appears below. |
This issue of Annals of Oncology includes a very interesting manuscript reporting the 15-year follow-up of two-thirds of the women initially randomized in a phase III trial of 5 years of fenretinide versus observation [1
]. These women, who were aged 3070 years old at the time of randomization had completed either breast conserving surgery or mastectomy for primary breast cancer with curative intent but were given no systemic therapy after primary surgical
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. Kerr Now the New Year reviving old desires Ann. Onc., January 1, 2007; 18(1): 3 - 3. [Full Text] [PDF] |
||||
